Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study-Reference-Cited by-同舟云学术

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study

Published:2009-01 Issue:1 Volume:157 Page:195-203
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Mohiuddin Syed M.,Pepine Carl J.,Kelly Maureen T.,Buttler Susan M.,Setze Carolyn M.,Sleep Darryl J.,Stolzenbach James C.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference19 articles.

1. Contemporary management of dyslipidemia in high-risk patients: Targets still not met;Yan;Am J Med,2006

2. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy;Fazio;Curr Atheroscler Rep,2004

3. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies;Hokanson;J Cardiovasc Risk,1996

4. Risk of cardiovascular events in patients at optimal values for combined lipid parameters;Stanek;Curr Med Res Opin,2007

5. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina;Fraker;J Am Coll Cardiol,2007

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome-Based Reimbursement: The Solution to High Drug Spending?;Manufacturing & Service Operations Management;2022-07

2. The Effect of Fibrates on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis of Randomised Studies;Journal of Clinical Medicine;2022-01-31

3. Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials;PLOS ONE;2021-02-09

4. Fenofibrate and Dyslipidemia: Still a Place in Therapy?;Drugs;2018-08-29

5. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development;International Journal of Molecular Sciences;2018-07-27